301: Biotech mega-rounds, a cancer vaccine se...

Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LO ...  Show more

What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Re ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more

Barron's senior managing editor Lauren R. Rublin and healthcare industry reporter Josh Nathan-Kazis discuss the outlook for healthcare stocks, and the latest news on Covid-19 treatments and vaccines. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information ab ...  Show more

CEO hits out against a short thesis and says 10-K delay won't affect customers. (0:16) Tesla's robotaxi goes to Hollywood. (3:39) Goldman loves gold. (4:29) Show Notes JPMorgan cut to Hold, BofA and Wells Fargo raised to Buy at Deutsche Bank Novo Nordisk warns of continued Ozempi ...  Show more

Dr. Vino Palli, CEO of MiDoctor Urgent Care, discusses the Covid virus and vaccinations. Businessweek Technology Editor Joshua Brustein talks about his Businessweek Magazine story Afghanistan War Turns a U.S. Military Startup Into a Unicorn. Bloomberg News Financial Regulations R ...  Show more